Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy
Panelists discuss how treatment decisions in metastatic melanoma involve balancing the benefits of immunotherapy versus targeted therapy, taking into account factors such as tumor genetics, patient response, and tolerability.
Now Viewing
EP: 1.Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy
EP: 2.Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma
EP: 3.Indirect Treatment Comparison: RELATIVITY-047 and CheckMate 067
EP: 4.Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma
EP: 5.Insight on Treating Patients With Melanoma With Brain Metastases
EP: 6.Expert Insight on Using Dual-IO Regimens for Melanoma in Real-World Practice
EP: 7.Potential Roles for First-Line Targeted Therapy for Advanced Melanoma
EP: 8.Key Takeaways From ITC Analysis of First-Line Dual-IO Treatments in Advanced Melanoma
EP: 9.Nivolumab Combinations Show Best Treatment Options for Advanced Melanoma
Recent Videos
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
